OBJECTIVES: The incidence of Crohn’s Disease (CD) in Taiwan has been increasing. The Asia Pacific Association of Gastroenterology Working Group on Inflammatory Bowel Disease recommends early biologic use for induction&maintenance therapy of refractory/fistulizing CD. Since July1, 2011, one biologic (adalimumab) has been reimbursed by Taiwan’s National Health Insurance (NHI); use is restricted to moderate/severe CD patients without satisfactory conventional therapy response. In this study, we aimed to investigate real-life treatment and biologic effectiveness in CD, in Taiwan. METHODS: The 2009-2013 NHI Research Database medical claims and catastrophic-illness-certificate (CIC) dataset were used. Patients eligible for CIC were divided into early and late cohorts (January1 2010-July1 2011 and July2 2011-December31 2012, respectively). An adalimumab cohort was also identified in the study period January 1 2010 – December 31 2013. Medication use within 3/6/12 months since CIC eligibility in early and late cohorts and indicators of loss-of-response in the adalimumab cohort were described. RESULTS: There were 72 CD patients in the early and 137 in the late cohort. Average age was 41 years, with a male preponderance in both cohorts. Most patients used 5-ASA (81/86/88% in early cohort; 79/82/84% in late cohort). Thiopurine use was 14/18/26% (early cohort) and 26/29/35% (late cohort). Systemic steroid use was 54/57/68% (early cohort) and 55/60/64% (late cohort). Adalimumab use was 1/3/7% in early cohort and 10/16/22% in late cohort. N=49 adalimumab users had follow-up of >40 weeks; median treatment duration was 17.0 months. Of these, 10% (n=5) received IBD-related surgery, while 47% (n=23) had ER-visit due to IBD from initial dose to end of follow-up. And, 29% (n=14) discontinued adalimumab treatment, of whom 14% (n=2) had IBD-related surgery and 57% (n=8) required IBD ER-visits from initial dose to end of follow-up. CONCLUSIONS: Thiopurine and adalimumab use increased over time. Further study on the association between biologic persistence and treatment effectiveness is ongoing.